These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33277782)

  • 1. EZH2 is a potential prognostic predictor of glioma.
    Chen YN; Hou SQ; Jiang R; Sun JL; Cheng CD; Qian ZR
    J Cell Mol Med; 2021 Jan; 25(2):925-936. PubMed ID: 33277782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
    Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
    Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unveiling the therapeutic potential of IHMT-337 in glioma treatment: targeting the EZH2-SLC12A5 axis.
    Zhang H; Wang Z; Qiao X; Peng N; Wu J; Chen Y; Cheng C
    Mol Med; 2024 Jun; 30(1):91. PubMed ID: 38886655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIM37 interacts with EZH2 to epigenetically suppress PTCH1 and regulate stemness in glioma stem cells through sonic hedgehog pathway.
    Cai L; Liu Y; Li Y; Liu B; Cao Y; Yang W; Wang B; Sun T
    J Neurooncol; 2024 Sep; 169(2):269-279. PubMed ID: 38884661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Enhancer of Zeste Homolog 2 (EZH2) Expression on Brain Glioma Cell Proliferation and Tumorigenesis.
    Cheng T; Xu Y
    Med Sci Monit; 2018 Oct; 24():7249-7255. PubMed ID: 30305602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis.
    Du TQ; Liu R; Zhang Q; Luo H; Liu Z; Sun S; Wang X
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunostaining of Increased Expression of Enhancer of Zeste Homolog 2 (EZH2) in Diffuse Midline Glioma H3K27M-Mutant Patients with Poor Survival.
    Karlowee V; Amatya VJ; Takayasu T; Takano M; Yonezawa U; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
    Pathobiology; 2019; 86(2-3):152-161. PubMed ID: 31096221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.
    Zhao G; Deng Z; Li X; Wang H; Chen G; Feng M; Zhou Y
    Exp Brain Res; 2023 Oct; 241(10):2409-2418. PubMed ID: 37644332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
    Hu Y; Tu Z; Lei K; Huang K; Zhu X
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the correlation between Zeste enhancer homolog 2 (EZH2) mRNA expression and the prognosis of mesothelioma patients and immune infiltration.
    Fan K; Zhang CL; Zhang BH; Gao MQ; Sun YC
    Sci Rep; 2022 Oct; 12(1):16583. PubMed ID: 36195655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pivotal Immunomodulatory and Anti-Inflammatory Effect of Histone-Lysine N-Methyltransferase in the Glioma Microenvironment: Its Biomarker and Therapy Potentials.
    Richard SA; Eugene KD
    Anal Cell Pathol (Amst); 2021; 2021():4907167. PubMed ID: 34745848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
    Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
    Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/β-catenin signaling pathway by targeting EZH2.
    Xu H; Zhao G; Zhang Y; Jiang H; Wang W; Zhao D; Hong J; Yu H; Qi L
    Stem Cell Res Ther; 2019 Dec; 10(1):381. PubMed ID: 31842978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 Palmitoylation Mediated by ZDHHC5 in p53-Mutant Glioma Drives Malignant Development and Progression.
    Chen X; Ma H; Wang Z; Zhang S; Yang H; Fang Z
    Cancer Res; 2017 Sep; 77(18):4998-5010. PubMed ID: 28775165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients.
    Wu Z; Wang Q; Wang L; Li G; Liu H; Fan F; Li Z; Li Y; Tu Y
    J Neurol Sci; 2013 Dec; 335(1-2):191-6. PubMed ID: 24139839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
    Chen J; Hou C; Wang P; Yang Y; Zhou D
    World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long non-coding RNA LINC00526 represses glioma progression via forming a double negative feedback loop with AXL.
    Yan J; Xu C; Li Y; Tang B; Xie S; Hong T; Zeng E
    J Cell Mol Med; 2019 Aug; 23(8):5518-5531. PubMed ID: 31240814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant Activation of β-Catenin Signaling Drives Glioma Tumorigenesis via USP1-Mediated Stabilization of EZH2.
    Ma L; Lin K; Chang G; Chen Y; Yue C; Guo Q; Zhang S; Jia Z; Huang TT; Zhou A; Huang S
    Cancer Res; 2019 Jan; 79(1):72-85. PubMed ID: 30425057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.